Republic of the Philippines
Department of Health
Food and Drug Administration
Civic Drive, Filinvest Corporate City
Alabang, Muntinlupa City

CERTIFICATE OF LISTING OF IDENTICAL DRUG PRODUCT

Pursuant to the provisions of Republic Act (R.A.) No. 3720 as amended, known as the Foods, Drugs, Devices and Cosmetics Act, and consistent with R.A. No. 6675, known as the Generics Act of 1988 and R.A. No. 9711, otherwise known as the Food and Drug Administration Act of 2009, the product described hereunder has been found to conform with the requirements and standards for marketing authorization of pharmaceutical products per existing regulations in force as of date hereof.

Registration Number:	**HRP-417-02**
Generic Name:	Tretinoin + Hydroquinone
Brand Name:	Naturawhite
Dosage Strength & Form:	10 mg/2g per 100 mL (0.01%/2%) Topical Solution
Pharmacologic Category:	Exfoliant / Anti-Acne / Depigmenting
Classification:	Household Remedy (HR)
Approved Shelf-life:	24 months
Storage Condition:	Store at temperatures not exceeding 30°C
Packaging:	HDPE Opaque White Flat Type Bottle x 60 mL with HDPE Plastic Cap (Box of 1's)
Manufacturer:	Refinette Cosmetic Manufacturing Corporation 143 Old Tabang Road, Tabang, Guiguinto, Bulacan
Distributor:	Unlimited Network of Opportunities International Corporation 108 Octo Arts Building 2 Panay Avenue, Quezon City, Metro Manila

The Certificate of Listing to the above Distributor shall be valid until **15 March 2026.** which covers the unexpired term of the Principal CPR, subject to the conditions listed on the reverse side. No changes in the ownership, registrant's address/location, manufacturer, excipients, formulation, dosage form, strength, therapeutic indication, manufacturing process, labelling and commercial presentation, and packaging of the Principal product covered by the Principal CPR without prior approval of this Office.

This Certificate of Listing is subject to suspension, cancellation or recall should any violation of R.A. No. 3720, R.A. No. 6675 and R.A. No. 9711 and/or regulations issued thereunder involving the product be committed.

Witness My Hand and Seal of this Office, this **21 May 2022**

By the Authority of the Director-General:

Jesusa Joyce N. Cirunay, RPh

Director IV, Center for Drug Regulation and Research

This electronic-clidp (eCLIDP) is computer generated and does not require signature

Registration Number: **HRP-417-02**

SPECIAL CONDITION:

Provided that nothing in the registration of the product herein granted shall be interpreted or construed as an endorsement or representation by FDA, that registrant has the right or privilege to the use of the name or brand so registered, Registrant hereby agrees and affirms to indemnify and/or hold FDA free and harmless against any and all third-party claims on infringement of patent, trademark or intellectual property right arising from the registration of the product.

Subject to post-marketing surveillance of the marketing authorization holder's strict compliance to the Generic Labeling Requirements following the applicable provisions of A.O No. 2016-0008 for drug products for human use and A.O. No. 105 s. 1991 for veterinary drug products.

Subject to satisfactory compliance to the post-approval commitments detailed in this CPR/ in the letter accompanying this CPR.

REMARKS:

This Certificate of Listing of Identical Drug Product (CLIDP) is revalidated to reflect the full validity until 15 March 2026.

Processed under AO No. 31 s. 2005.